At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 3, 2026 at 08:30 ET
Alpha Tau Medical announced a strategic collaboration with Tolmar Inc. for exclusive U.S. commercialization of Alpha DaRT in prostate cancer, with an option for bladder cancer. Tolmar will invest $20M at an $11.99/share premium (25% above 30-day VWAP), pay $15M for manufacturing capacity, and provide up to $161.5M in milestones. The deal validates Alpha Tau's platform and provides non-dilutive capital, but the stock is already up significantly on prior reports.
- Tolmar gets exclusive U.S. commercialization rights for prostate cancer (20-year term from first sale) with option for bladder cancer.
- Tolmar makes $20M equity investment at $11.99/share (25% premium to 30-day VWAP) and $15M manufacturing facility investment.
- Up to $161.5M in clinical, regulatory, and commercial milestones for the first indication.
- Alpha Tau will manufacture Alpha DaRT and sell to Tolmar at 60% of net sales price (subject to adjustments).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access